Results 11 to 20 of about 46,034 (246)
Thromboembolic complications of polycythemia: Polycythemia vera versus smokers' polycythemia [PDF]
Journal of Vascular Surgery, 1993 This report compares patients with the hypercoagulable state of polycythemia vera to patients with secondary polycythemia caused by tobacco use to determine whether the incidence of thromboembolic events is equivalent.The medical records of 146 patients with the diagnosis of polycythemia between 1977 to 1990 were reviewed.
T H, Schwarcz +5 more
openaire +2 more sources
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
Blood Cancer Journal, 2022 We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
A. Carobbio +10 more
semanticscholar +1 more source
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia, 2021 Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar +1 more source
Journal of Urology, 2022 Purpose: An unsafe hematocrit threshold for men receiving testosterone therapy (TT) has never been tested. This study seeks to determine whether secondary polycythemia among men receiving TT confers an increased risk of major adverse cardiovascular ...
J. Ory +4 more
semanticscholar +1 more source
Journal of Medical Case Reports, 2023 Background Absolute polycythemia can be primary or secondary. Erythropoietin-producing diseases (for example, hypoxia) are the major cause of secondary polycythemia. There are reports of polycythemia secondary to hydronephrosis. However, to our knowledge,
Yuriko Hajika +3 more
doaj +1 more source
Cancer, 2022 Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown.
A. Álvarez-Larrán +29 more
semanticscholar +1 more source
Genetic Background of Polycythemia Vera
Genes, 2022 Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases.
Mathilde Regimbeau +3 more
semanticscholar +1 more source
Hepcidin Mimetics in Polycythemia Vera: Resolving the Irony of Iron deficiency and Erythrocytosis
Current opinion in hematology, 2022 Purpose of review Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders.
S. Handa +3 more
semanticscholar +1 more source
American journal of hematology/oncology, 2020 Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding ...
A. Tefferi, T. Barbui
semanticscholar +1 more source
International Journal of COPD, 2022 Purpose Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) are associated with polycythemia. However, there still remain unanswered questions about the relationship between overlap syndrome (OVS), where OSA and COPD coexist ...
Zhao-Fu Zeng +6 more
semanticscholar +1 more source